MA45290A - Procédés et compositions d'agents biologiquement actifs - Google Patents
Procédés et compositions d'agents biologiquement actifsInfo
- Publication number
- MA45290A MA45290A MA045290A MA45290A MA45290A MA 45290 A MA45290 A MA 45290A MA 045290 A MA045290 A MA 045290A MA 45290 A MA45290 A MA 45290A MA 45290 A MA45290 A MA 45290A
- Authority
- MA
- Morocco
- Prior art keywords
- compositions
- processes
- biologically active
- active agents
- agents
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
- C12N2310/141—MicroRNAs, miRNAs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/16—Aptamers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3515—Lipophilic moiety, e.g. cholesterol
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/32—Special delivery means, e.g. tissue-specific
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Virology (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662331961P | 2016-05-04 | 2016-05-04 | |
| US201662405810P | 2016-10-07 | 2016-10-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA45290A true MA45290A (fr) | 2019-03-13 |
Family
ID=60203379
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA045290A MA45290A (fr) | 2016-05-04 | 2017-05-03 | Procédés et compositions d'agents biologiquement actifs |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US20190249173A1 (fr) |
| EP (1) | EP3452597A4 (fr) |
| JP (3) | JP2019516679A (fr) |
| CN (1) | CN109462995A (fr) |
| MA (1) | MA45290A (fr) |
| WO (1) | WO2017192679A1 (fr) |
Families Citing this family (122)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9394333B2 (en) | 2008-12-02 | 2016-07-19 | Wave Life Sciences Japan | Method for the synthesis of phosphorus atom modified nucleic acids |
| MX342945B (es) | 2009-07-06 | 2016-10-18 | Ontorii Inc * | Profármacos de ácido nucleico novedosos y métodos de uso de los mismos. |
| DK2620428T3 (da) | 2010-09-24 | 2019-07-01 | Wave Life Sciences Ltd | Asymmetrisk hjælpegruppe |
| US9605019B2 (en) | 2011-07-19 | 2017-03-28 | Wave Life Sciences Ltd. | Methods for the synthesis of functionalized nucleic acids |
| KR20240148947A (ko) | 2012-07-13 | 2024-10-11 | 웨이브 라이프 사이언시스 리미티드 | 키랄 제어 |
| SG11201500239VA (en) | 2012-07-13 | 2015-03-30 | Wave Life Sciences Japan | Asymmetric auxiliary group |
| WO2015108047A1 (fr) | 2014-01-15 | 2015-07-23 | 株式会社新日本科学 | Adjuvant d'acide nucléique chiral possédant une activité d'induction d'immunité, et activateur d'induction d'immunité |
| WO2015108048A1 (fr) | 2014-01-15 | 2015-07-23 | 株式会社新日本科学 | Adjuvant d'acide nucléique chiral ayant un effet antitumoral et agent antitumoral |
| ES2917473T3 (es) | 2014-01-16 | 2022-07-08 | Wave Life Sciences Ltd | Diseño quiral |
| CA2968336C (fr) | 2014-12-17 | 2021-11-23 | Proqr Therapeutics Ii B.V. | Construction pour l'edition en site d'un nucleotide d'adenosine dans l'arn cible |
| CN108025089A (zh) | 2015-07-22 | 2018-05-11 | 波涛生命科学有限公司 | 寡核苷酸组合物及其方法 |
| SG10201912902TA (en) * | 2015-10-09 | 2020-02-27 | Wave Life Sciences Ltd | Oligonucleotide compositions and methods thereof |
| AU2017234150B2 (en) | 2016-03-13 | 2021-09-16 | Wave Life Sciences Ltd. | Compositions and methods for phosphoramidite and oligonucleotide synthesis |
| KR102775461B1 (ko) | 2016-04-01 | 2025-02-28 | 어비디티 바이오사이언시스 인크. | 핵산-폴리펩타이드 조성물 및 이의 용도 |
| CN109477108A (zh) | 2016-05-04 | 2019-03-15 | 波涛生命科学有限公司 | 寡核苷酸组合物和其方法 |
| WO2017210647A1 (fr) | 2016-06-03 | 2017-12-07 | Wave Life Sciences Ltd. | Oligonucléotides, compositions et méthodes associées |
| CN109477103A (zh) | 2016-06-22 | 2019-03-15 | ProQR治疗上市公司Ⅱ | 单链rna-编辑寡核苷酸 |
| EP3507366B1 (fr) | 2016-09-01 | 2020-10-07 | ProQR Therapeutics II B.V. | Oligonucléotides d'édition d'arn simple brin chimiquement modifiés |
| JP7296882B2 (ja) | 2016-11-23 | 2023-06-23 | ウェイブ ライフ サイエンシズ リミテッド | ホスホラミダイト及びオリゴヌクレオチド合成のための組成物及び方法 |
| KR102810425B1 (ko) | 2016-12-19 | 2025-05-21 | 사렙타 쎄러퓨틱스 인코퍼레이티드 | 근육 이상증에 대한 엑손 스킵핑 올리고머 결합체 |
| KR102646318B1 (ko) | 2016-12-19 | 2024-03-12 | 사렙타 쎄러퓨틱스 인코퍼레이티드 | 근육 이상증에 대한 엑손 스킵핑 올리고머 결합체 |
| HRP20240705T1 (hr) | 2016-12-19 | 2024-08-30 | Sarepta Therapeutics, Inc. | Oligomerni konjugati koji preskaču egzon za mišićnu distrofiju |
| SG10202107429WA (en) | 2017-01-06 | 2021-08-30 | Avidity Biosciences Inc | Nucleic acid-polypeptide compositions and methods of inducing exon skipping |
| WO2018223056A1 (fr) | 2017-06-02 | 2018-12-06 | Wave Life Sciences Ltd. | Compositions d'oligonucléotides et leurs procédés d'utilisation |
| US11597927B2 (en) | 2017-06-02 | 2023-03-07 | Wave Life Sciences Ltd. | Oligonucleotide compositions and methods of use thereof |
| WO2018237194A1 (fr) | 2017-06-21 | 2018-12-27 | Wave Life Sciences Ltd. | Composés, compositions et procédés de synthèse |
| GB201711809D0 (en) | 2017-07-21 | 2017-09-06 | Governors Of The Univ Of Alberta | Antisense oligonucleotide |
| CA3072076A1 (fr) | 2017-08-08 | 2019-02-14 | Wave Life Sciences Ltd. | Compositions oligonucleotidiques et methodes associees |
| SG11202000276YA (en) | 2017-09-18 | 2020-04-29 | Wave Life Sciences Ltd | Technologies for oligonucleotide preparation |
| EA201991450A1 (ru) | 2017-09-22 | 2019-12-30 | Сарепта Терапьютикс, Инк. | Конъюгаты олигомеров для пропуска экзона при мышечной дистрофии |
| EP3687519A1 (fr) | 2017-09-28 | 2020-08-05 | Sarepta Therapeutics, Inc. | Polythérapies pour traiter une dystrophie musculaire |
| JP2020536060A (ja) | 2017-09-28 | 2020-12-10 | サレプタ セラピューティクス， インコーポレイテッド | 筋ジストロフィーを処置するための併用療法 |
| EP3687577A1 (fr) | 2017-09-28 | 2020-08-05 | Sarepta Therapeutics, Inc. | Polythérapies pour traiter une dystrophie musculaire |
| WO2019075357A1 (fr) | 2017-10-12 | 2019-04-18 | Wave Life Sciences Ltd. | Compositions d'oligonucléotides et procédés associés |
| CN118638787A (zh) | 2017-12-06 | 2024-09-13 | 艾维迪提生物科学公司 | 治疗肌萎缩和强直性肌营养不良的组合物和方法 |
| EP3728300A4 (fr) * | 2017-12-20 | 2021-08-11 | Lunella Biotech, Inc. | Ciblage de la fission mitochondriale par l'intermédiaire de dérivés de mdivi-1 |
| BR112020020670A2 (pt) | 2018-04-12 | 2021-03-02 | Wave Life Sciences Ltd. | composição de oligonucleotídeo, composição farmacêutica, método para alterar o splicing de uma transcrição alvo, método para tratar distrofia muscular, método para preparar um oligonucleotídeo ou uma composição de oligonucleotídeo do mesmo e oligonucleotídeo |
| MX2020011570A (es) | 2018-05-07 | 2020-11-24 | Alnylam Pharmaceuticals Inc | Administracion extrahepatica. |
| TWI844541B (zh) | 2018-05-11 | 2024-06-11 | 新加坡商波濤生命科學有限公司 | 寡核苷酸組成物及其使用方法 |
| GB201808146D0 (en) | 2018-05-18 | 2018-07-11 | Proqr Therapeutics Ii Bv | Stereospecific Linkages in RNA Editing Oligonucleotides |
| US10765760B2 (en) | 2018-05-29 | 2020-09-08 | Sarepta Therapeutics, Inc. | Exon skipping oligomer conjugates for muscular dystrophy |
| EP3802556A1 (fr) * | 2018-05-30 | 2021-04-14 | DTX Pharma, Inc. | Composés d'acide nucléique modifiés par des lipides et procédés |
| EP3806868A4 (fr) | 2018-06-13 | 2022-06-22 | Sarepta Therapeutics, Inc. | Oligomères induisant un saut d'exon pour la dystrophie musculaire |
| TW202449155A (zh) | 2018-07-27 | 2024-12-16 | 美商薩羅塔治療公司 | 用於肌肉萎縮症之外顯子跳躍寡聚物 |
| US12018087B2 (en) | 2018-08-02 | 2024-06-25 | Dyne Therapeutics, Inc. | Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject |
| US12370264B1 (en) | 2018-08-02 | 2025-07-29 | Dyne Therapeutics, Inc. | Complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and method of delivering oligonucleotide to a subject |
| AU2019316103B2 (en) | 2018-08-02 | 2026-02-19 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
| WO2020028832A1 (fr) | 2018-08-02 | 2020-02-06 | Dyne Therapeutics, Inc. | Complexes de ciblage musculaire et leurs utilisations pour le traitement de dystrophinopathies |
| US12097263B2 (en) | 2018-08-02 | 2024-09-24 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| US11168141B2 (en) | 2018-08-02 | 2021-11-09 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| US11911484B2 (en) | 2018-08-02 | 2024-02-27 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| EP3894559A4 (fr) | 2018-12-03 | 2023-04-05 | Triplet Therapeutics, Inc. | Méthodes thérapeutiques pour les maladies par expansion de répétitions trinucléotidiques associés à une activité mlh3 |
| SG11202104960PA (en) | 2018-12-13 | 2021-06-29 | Sarepta Therapeutics Inc | Exon skipping oligomer conjugates for muscular dystrophy |
| WO2020132263A1 (fr) * | 2018-12-20 | 2020-06-25 | Aegis Therapeutics, Inc. | Compositions, dispositifs et procédés de traitement de troubles reposant sur la surdose et la récompense |
| CN109799216B (zh) * | 2018-12-29 | 2021-11-12 | 佛山科学技术学院 | 一种基于吲哚箐绿纳米的荧光oct双模成像方法和装置 |
| WO2020158636A1 (fr) * | 2019-01-29 | 2020-08-06 | 国立大学法人東京大学 | Procédé pour introduire un acide nucléique, etc., dans une cellule |
| CN109870583B (zh) * | 2019-04-15 | 2020-03-06 | 德阳市人民医院 | 急性胰腺炎相关的代谢物及其应用 |
| JP2022528725A (ja) | 2019-04-18 | 2022-06-15 | サレプタ セラピューティクス， インコーポレイテッド | 筋ジストロフィーを治療するための組成物 |
| JP7186442B2 (ja) * | 2019-04-22 | 2022-12-09 | 国立研究開発法人産業技術総合研究所 | 新規スクアレン誘導体および抗炎症剤 |
| EP3959319A4 (fr) | 2019-04-25 | 2023-06-07 | Avidity Biosciences, Inc. | Compositions d'acide nucléique et méthodes de saut multi-exon |
| CN114096267B (zh) * | 2019-05-22 | 2025-03-18 | 柏欧韦股份有限公司 | 特利加压素制剂 |
| BR112021024764A2 (pt) | 2019-07-12 | 2022-04-19 | Daiichi Sankyo Co Ltd | Oligonucleotídeo antissenso capaz de alterar o splicing de pré-mrna de dux4 |
| CN110527698B (zh) * | 2019-08-23 | 2021-10-01 | 温氏食品集团股份有限公司 | 一种利用小分子化合物提高基因组定点插入效率的方法 |
| CN115348883B (zh) * | 2019-11-27 | 2024-11-15 | 诺华股份有限公司 | 用于治疗杜兴氏肌营养不良症的化合物和方法 |
| CN111063870B (zh) * | 2019-11-27 | 2021-09-24 | 深圳先进技术研究院 | 纳米材料及其制备方法、电极和二次电池 |
| CN111012788B (zh) * | 2019-12-12 | 2021-01-15 | 武汉职业技术学院 | 硝唑尼特和替唑尼特在制备抗猪繁殖与呼吸综合征病毒药物中的应用 |
| CN111055603B (zh) * | 2019-12-31 | 2021-11-05 | 安徽省粤隆印刷科技有限公司 | 一种防止残剩油墨过度乳化和形成残渣的包装盒印刷工艺 |
| WO2021178237A2 (fr) * | 2020-03-01 | 2021-09-10 | Wave Life Sciences Ltd. | Compositions oligonucléotidiques et méthodes associées |
| AU2021237465A1 (en) | 2020-03-19 | 2022-10-13 | Avidity Biosciences, Inc. | Compositions and methods of treating Facioscapulohumeral muscular dystrophy |
| CN111358955B (zh) * | 2020-04-01 | 2023-05-02 | 重庆理工大学 | 一种用于治疗脂质代谢疾病的炎症靶向的宾达利纳米粒、制备方法及其应用 |
| CN111249298B (zh) * | 2020-04-08 | 2021-03-12 | 曲阜师范大学 | 一种含有马杜霉素和顺铂的抗癌药物组合物 |
| IL298406A (en) | 2020-05-22 | 2023-01-01 | Wave Life Sciences Ltd | Double stranded oligonucleotide compositions and methods relating thereto |
| IT202000012577A1 (it) * | 2020-05-27 | 2021-11-27 | Univ Degli Studi Roma La Sapienza | Composizione farmaceutica per l’inibizione chimica di tgs1 come trattamento terapeutico per le telomeropatie |
| AR122534A1 (es) | 2020-06-03 | 2022-09-21 | Triplet Therapeutics Inc | Métodos para el tratamiento de los trastornos de expansión por repetición de nucleótidos asociados con la actividad de msh3 |
| CN111789859A (zh) * | 2020-07-20 | 2020-10-20 | 中国人民解放军海军军医大学 | 地塞米松在制备预防或缓解水母蜇伤药物中的应用 |
| UY39444A (es) * | 2020-09-30 | 2022-04-29 | Biomarin Tech Bv | Oligonucleótido |
| EP3978608A1 (fr) * | 2020-10-05 | 2022-04-06 | SQY Therapeutics | Composé oligomère de sauvetage de dystrophine chez des patients atteints de dmd durant des sauts d'exon-51 |
| CN115216474B (zh) * | 2021-04-15 | 2025-09-30 | 武汉大学 | 促进pd-l1外显子3跳跃的反义寡核苷酸及其应用 |
| US11672872B2 (en) | 2021-07-09 | 2023-06-13 | Dyne Therapeutics, Inc. | Anti-transferrin receptor antibody and uses thereof |
| JP2024525608A (ja) | 2021-07-09 | 2024-07-12 | ダイン セラピューティクス，インコーポレーテッド | ジストロフィン異常症を処置するための筋標的化複合体および製剤 |
| US11633498B2 (en) | 2021-07-09 | 2023-04-25 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| US11771776B2 (en) | 2021-07-09 | 2023-10-03 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| US11969475B2 (en) | 2021-07-09 | 2024-04-30 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
| US11638761B2 (en) | 2021-07-09 | 2023-05-02 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy |
| CN113520995B (zh) * | 2021-08-16 | 2023-03-10 | 海南鑫开源医药科技有限公司 | 一种离子敏感型眼用原位凝胶、其制备方法及应用 |
| AU2022345986A1 (en) * | 2021-09-16 | 2024-03-07 | Dyne Therapeutics, Inc. | Dosing of muscle targeting complexes for treating dystrophinopathies |
| CN118265544A (zh) | 2021-09-16 | 2024-06-28 | 艾维迪提生物科学公司 | 治疗面肩肱型肌营养不良的组合物和方法 |
| AU2022358322A1 (en) | 2021-09-30 | 2024-05-16 | Sarepta Therapeutics, Inc. | Antisense oligonucleotides having one or more abasic units |
| US20250154504A1 (en) | 2022-02-14 | 2025-05-15 | Proqr Therapeutics Ii B.V. | Guide oligonucleotides for nucleic acid editing in the treatment of hypercholesterolemia |
| US12071621B2 (en) | 2022-04-05 | 2024-08-27 | Avidity Biosciences, Inc. | Anti-transferrin receptor antibody-PMO conjugates for inducing DMD exon 44 skipping |
| IL316143A (en) | 2022-04-15 | 2024-12-01 | Dyne Therapeutics Inc | Muscle targeting complexes and formulations for the treatment of myotonic dystrophy |
| US20260027237A1 (en) | 2022-07-15 | 2026-01-29 | Proqr Therapeutics Ii B.V. | Chemically modified oligonucleotides for adar-mediated rna editing |
| EP4555086A1 (fr) | 2022-07-15 | 2025-05-21 | ProQR Therapeutics II B.V. | Oligonucléotides pour édition d'arn médiée par adar et leur utilisation |
| EP4590311A2 (fr) | 2022-09-21 | 2025-07-30 | Sarepta Therapeutics, Inc. | Efficacité du saut d'exon médié par un oligonucléotide antisens dans le traitement de la dmd |
| GB202215614D0 (en) | 2022-10-21 | 2022-12-07 | Proqr Therapeutics Ii Bv | Heteroduplex rna editing oligonucleotide complexes |
| JP2025536808A (ja) | 2022-11-24 | 2025-11-07 | プロキューアール・セラピューティクス・セカンド・ベスローテン・フェンノートシャップ | 遺伝性ｈｆｅヘモクロマトーシスの治療のためのアンチセンスオリゴヌクレオチド |
| GB202218090D0 (en) | 2022-12-01 | 2023-01-18 | Proqr Therapeutics Ii Bv | Antisense oligonucleotides for the treatment of aldehyde dehydrogenase 2 deficiency |
| JP2025540146A (ja) | 2022-12-09 | 2025-12-11 | プロキューアール セラピューティクス ツー ベスローテン フェンノートシャップ | 心血管疾患の治療のためのアンチセンスオリゴヌクレオチド |
| GB202300865D0 (en) | 2023-01-20 | 2023-03-08 | Proqr Therapeutics Ii Bv | Delivery of oligonucleotides |
| EP4669753A1 (fr) | 2023-02-20 | 2025-12-31 | ProQR Therapeutics II B.V. | Oligonucléotides antisens pour le traitement d'une maladie cardiovasculaire athérosclérotique |
| US12396981B2 (en) | 2023-03-09 | 2025-08-26 | William Shulman | Methods of using DMT |
| WO2024206175A1 (fr) | 2023-03-24 | 2024-10-03 | Proqr Therapeutics Ii B.V. | Oligonucléotides antisens pour le traitement de troubles neurologiques |
| GB202304363D0 (en) | 2023-03-24 | 2023-05-10 | Proqr Therapeutics Ii Bv | Chemically modified antisense oligonucleotides for use in RNA editing |
| CN121002181A (zh) | 2023-03-27 | 2025-11-21 | ProQR治疗上市公司Ⅱ | 用于治疗肝脏疾病的反义寡核苷酸 |
| WO2024227040A1 (fr) | 2023-04-27 | 2024-10-31 | Sarepta Therapeutics, Inc. | Oligomères antisens pour le traitement d'une néphropathie chronique |
| TW202516003A (zh) | 2023-06-16 | 2025-04-16 | 荷蘭商Ｐｒｏｑｒ治療上市公司Ｉｉ | 用於治療神經退化性疾病之反義寡核苷酸 |
| AU2024287308A1 (en) | 2023-07-13 | 2025-12-18 | Korro Bio, Inc. | Rna-editing oligonucleotides and uses thereof |
| CN116754689A (zh) * | 2023-07-27 | 2023-09-15 | 苏州和合医学检验有限公司 | 一种高效液相色谱串联质谱法检测5种药物的方法及应用 |
| CN117099681B (zh) * | 2023-08-28 | 2024-07-05 | 南京农业大学 | 一种利用紫杉醇加倍玉米单倍体的方法 |
| WO2025051946A1 (fr) | 2023-09-07 | 2025-03-13 | Proqr Therapeutics Ii B.V. | Oligonucléotides antisens pour le traitement de troubles métaboliques |
| WO2025085810A2 (fr) | 2023-10-18 | 2025-04-24 | Sarepta Therapeutics, Inc. | Oligomères antisens pour le traitement de myopathies centronucléaires |
| AU2024369609A1 (en) | 2023-10-31 | 2025-12-11 | Korro Bio, Inc. | Oligonucleotides comprising phosphoramidate internucleotide linkages |
| WO2025104239A1 (fr) | 2023-11-16 | 2025-05-22 | Proqr Therapeutics Ii B.V. | Oligonucléotides antisens pour le traitement de galactosémie classique |
| WO2025128799A1 (fr) | 2023-12-12 | 2025-06-19 | Korro Bio, Inc. | Oligonucléotides d'édition d'arn double brin et leurs utilisations |
| WO2025132708A1 (fr) | 2023-12-20 | 2025-06-26 | Proqr Therapeutics Ii B.V. | Oligonucléotides antisens pour traitement de maladie de huntington |
| GB202404661D0 (en) | 2024-04-02 | 2024-05-15 | Proqr Therapeutics Ii Bv | Antisense oligoncleotides for the treatment of liver disease |
| WO2025213142A2 (fr) * | 2024-04-05 | 2025-10-09 | Wave Life Sciences Ltd. | Compositions d'oligonucléotides et procédés associés |
| WO2025224230A1 (fr) | 2024-04-25 | 2025-10-30 | Proqr Therapeutics Ii B.V. | Oligonucléotides antisens pour traitement de la stéatose hépatique |
| GB202410081D0 (en) | 2024-07-11 | 2024-08-28 | Proqr Therapeutics Ii Bv | Antisense oligonucleotides for the treatment of cardiovascular disease |
| WO2026022136A1 (fr) | 2024-07-23 | 2026-01-29 | Proqr Therapeutics Ii B.V. | Oligonucléotides antisens pour le traitement de troubles métaboliques |
| CN119015397B (zh) * | 2024-08-20 | 2025-04-18 | 广州医科大学附属中医医院(广州市中医中药研究所、广州市中医医院、广州中医药大学附属广州中医医院、广州市针灸医院) | 一种抑制人前列腺癌细胞增殖的白僵菌素组合物及其制备方法 |
| WO2026050243A1 (fr) | 2024-08-26 | 2026-03-05 | Korro Bio, Inc. | Oligonucléotides conjugués à des fractions galnac pour édition d'arn |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69008521T2 (de) * | 1989-03-07 | 1994-10-20 | Genentech Inc | Kovalente konjugate von lipiden und oligonukleotiden. |
| EP1012331B1 (fr) * | 1997-07-01 | 2006-03-29 | Isis Pharmaceuticals, Inc. | Compositions et procedes d'apport d'oligonucleotides par le tube digestif |
| US6676963B1 (en) * | 2000-10-27 | 2004-01-13 | Barnes-Jewish Hospital | Ligand-targeted emulsions carrying bioactive agents |
| US7511131B2 (en) * | 2002-11-13 | 2009-03-31 | Genzyme Corporation | Antisense modulation of apolipoprotein B expression |
| KR101298493B1 (ko) * | 2003-09-09 | 2013-08-21 | 제론 코포레이션 | 텔로머라제 억제를 위한 변형 올리고뉴클레오티드 |
| US7404969B2 (en) * | 2005-02-14 | 2008-07-29 | Sirna Therapeutics, Inc. | Lipid nanoparticle based compositions and methods for the delivery of biologically active molecules |
| US20100008937A1 (en) * | 2006-04-25 | 2010-01-14 | Immune Disease Institute, Inc. | Targeted delivery to leukocytes using non-protein carriers |
| US8097596B2 (en) * | 2006-06-30 | 2012-01-17 | Lakewood-Amedex, Inc. | Compositions and methods for the treatment of muscle wasting |
| DK2203173T3 (en) * | 2007-10-26 | 2016-02-29 | Academisch Ziekenhuis Leiden | Materials and methods for prevention of muscle diseases |
| CA2741629C (fr) * | 2008-10-27 | 2022-07-05 | Academisch Ziekenhuis Leiden | Procedes et moyens d'induction du saut de l'exon 45 dans l'arn pre-messager du gene de la dystrophie musculaire de duchenne |
| WO2011076807A2 (fr) * | 2009-12-23 | 2011-06-30 | Novartis Ag | Lipides, compositions lipidiques, et procédés d'utilisation associés |
| EP2582397A4 (fr) * | 2010-06-15 | 2014-10-29 | Isis Pharmaceuticals Inc | Composés et procédés pour moduler l'interaction entre des protéines et des acides nucléiques cibles |
| ES2917473T3 (es) * | 2014-01-16 | 2022-07-08 | Wave Life Sciences Ltd | Diseño quiral |
-
2017
- 2017-05-03 MA MA045290A patent/MA45290A/fr unknown
- 2017-05-03 EP EP17793227.4A patent/EP3452597A4/fr active Pending
- 2017-05-03 US US16/098,658 patent/US20190249173A1/en not_active Abandoned
- 2017-05-03 JP JP2018557083A patent/JP2019516679A/ja active Pending
- 2017-05-03 CN CN201780040364.4A patent/CN109462995A/zh active Pending
- 2017-05-03 WO PCT/US2017/030777 patent/WO2017192679A1/fr not_active Ceased
-
2022
- 2022-11-30 US US18/072,296 patent/US20230295617A1/en active Pending
-
2023
- 2023-03-16 JP JP2023041621A patent/JP7825588B2/ja active Active
-
2025
- 2025-04-10 JP JP2025064806A patent/JP2025108550A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2019516679A (ja) | 2019-06-20 |
| JP2023078293A (ja) | 2023-06-06 |
| EP3452597A1 (fr) | 2019-03-13 |
| WO2017192679A1 (fr) | 2017-11-09 |
| JP2025108550A (ja) | 2025-07-23 |
| CN109462995A (zh) | 2019-03-12 |
| US20230295617A1 (en) | 2023-09-21 |
| JP7825588B2 (ja) | 2026-03-06 |
| EP3452597A4 (fr) | 2020-05-06 |
| US20190249173A1 (en) | 2019-08-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA45290A (fr) | Procédés et compositions d'agents biologiquement actifs | |
| MA45270A (fr) | Compositions d'oligonucléotides et procédés associés | |
| EP3704239A4 (fr) | Compositions de casz et procédés d'utilisation | |
| EP3634430A4 (fr) | Agents multibiotiques et procédés d'utilisation de ceux-ci | |
| MA45688A (fr) | Compositions et procédés de potentialisation d'agents antimicrobiens | |
| MA46427A (fr) | Compositions d'oligonucléotides et procédés associés | |
| EP3596213A4 (fr) | Compositions et procédés d'amplification d'expression génique | |
| EP3630199A4 (fr) | Compositions d'oligonucléotides et leurs procédés d'utilisation | |
| EP3630788A4 (fr) | Compositions d'oligonucléotides et leurs procédés d'utilisation | |
| EP3630789A4 (fr) | Compositions d'oligonucléotides et leurs procédés d'utilisation | |
| EP3402493A4 (fr) | Composition d'organoïde neural et procédés d'utilisation | |
| EP3298168A4 (fr) | Agents réducteurs stabilisés et leurs procédés d'utilisation | |
| MA47499A (fr) | Anticorps anti-tau et leurs procédés d'utilisation | |
| EP3377042A4 (fr) | Substances et procédés de traitement de myopathies à base de titine et d'autres titinopathies | |
| EP3352774A4 (fr) | Compositions de flavonoïdes et procédés d'utilisation | |
| EP3313404A4 (fr) | Compositions thérapeutiques, associations et procédés d'utilisation | |
| EP3435956A4 (fr) | Compositions photo-stabilisées et leurs procédés d'utilisation | |
| EP3407976A4 (fr) | Compositions et utilisations d'agents alpha-adrénergiques | |
| EP3522882A4 (fr) | Compositions d'acides aminés et utilisations associées | |
| EP3635000A4 (fr) | Manabodies et procédés d'utilisation | |
| EP3496768A4 (fr) | Compositions antimicrobiennes et procédés d'utilisation associés. | |
| EP3302558A4 (fr) | Agents anticancéreux et procédés d'utilisation | |
| EP3706558A4 (fr) | Compositions et procédés d'aquaculture | |
| EP3689998A4 (fr) | Agent propulseur, composition d'agent propulseur et atomiseur | |
| EP3606465A4 (fr) | Schémas posologiques et compositions et procédés associés |